Abbott Laboratories vs Intersect Ent
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
In short
- Abbott Laboratories is the larger company by market value: $181.1 B against $914 M for Intersect Ent, 198 times as much (market caps of Oct 30, 2026 for Abbott Laboratories and Jan 7, 2022 for Intersect Ent). Intersect Ent's value is the last on file, from Jan 7, 2022: no market-data feed is connected for its exchange yet.
- Abbott Laboratories had more revenue: $44.3 B in the year to December 2025 against $107 M for Intersect Ent in the year to December 2021.
- Abbott Laboratories made a net profit of $6.5 B, while Intersect Ent made a net loss of $160 M.
- Abbott Laboratories keeps more of each dollar of sales: a net margin of 14.7% against -149.5% for Intersect Ent.
- Abbott Laboratories employs more people: 115,000 against 406 at Intersect Ent. Each employee brings in about $385,461 of revenue at Abbott Laboratories and $262,931 at Intersect Ent.
Market value, the same start = 100
From Jan 2020: how each one's value moved, whatever its size.
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | Abbott Laboratories ABT · #117 in the world | Intersect Ent XENT |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
| Founded | 1888 | 2003 |
| Size | ||
| Market cap | $181.1 B | $914 M* |
| Revenue | $44.3 B | $107 M |
| Net income | $6.5 B▲ best | $-160 M |
| Employees | 115,000 | 406 |
| Valuation | ||
| P/E ratio | 38.5× | — |
| Price to sales | 3.8× | — |
| Price to book | 3.5× | — |
| Free cash flow yield | 4.1% | — |
| Profitability | ||
| Gross margin | 56.4% | — |
| Operating margin | 18.2% | — |
| Net margin | 14.7% | — |
| Return on equity | 13.1% | — |
| Return on invested capital | 11.2% | — |
| Growth | ||
| Revenue growth | 5.7% | — |
| Revenue growth, 3 years a year | 0.5% | — |
| Earnings per share growth | -51.3% | — |
| Financial strength | ||
| Debt to equity | 0.3× | — |
| Cash | ||
| Free cash flow margin | 16.7% | — |
| Shareholder returns | ||
| Dividend yield | 2.3% | — |
| Shareholder yield | 2.8% | — |
| Strength scores | ||
| Piotroski F-score | 6 of 9 | — |
| Altman Z-score zone | safe | — |
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap Jan 2022 |
▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither
Questions and answers#
Which is bigger, Abbott Laboratories or Intersect Ent?
Abbott Laboratories is the larger company by market value: $181.1 B against $914 M for Intersect Ent, 198 times as much (market caps of Oct 30, 2026 for Abbott Laboratories and Jan 7, 2022 for Intersect Ent). Intersect Ent's value is the last on file, from Jan 7, 2022: no market-data feed is connected for its exchange yet.
Which makes more money, Abbott Laboratories or Intersect Ent?
Abbott Laboratories had more revenue: $44.3 B in the year to December 2025 against $107 M for Intersect Ent in the year to December 2021. Abbott Laboratories made a net profit of $6.5 B, while Intersect Ent made a net loss of $160 M.
Which is more profitable, Abbott Laboratories or Intersect Ent?
Abbott Laboratories keeps more of each dollar of sales: a net margin of 14.7% against -149.5% for Intersect Ent.
Which has more employees, Abbott Laboratories or Intersect Ent?
Abbott Laboratories employs more people: 115,000 against 406 at Intersect Ent. Each employee brings in about $385,461 of revenue at Abbott Laboratories and $262,931 at Intersect Ent.
More about Abbott Laboratories
More about Intersect Ent
Sources#
Every figure on this page comes from these, with the date shown next to it.